Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors
作者:Vanangamudi Murugesan、Vinay S. Tiwari、Reshu Saxena、Rajkamal Tripathi、Ramesh Paranjape、Smita Kulkarni、Nandini Makwana、Rahul Suryawanshi、Seturam B. Katti
DOI:10.1016/j.bmc.2011.09.018
日期:2011.11
respectively. Structure–activity relationship (SAR) studies demonstrated the importance of the lipophilic bulky substituent pattern on compact heteroaryl ring at N-3, replacement of C4′ at C-2 phenyl by trivalent bioisosteric nitrogen and dihalo groups at C-2 aryl/heteroaryl of thiazolidin-4-ones is crucial for anti-HIV-1 activity. Molecular modeling of compounds 4, 5, 8 and 12 in complex with HIV-1 RT demonstrate
基于合理的药物设计方法,合成了一系列在位置C-2和N-3处带有不同芳基/杂芳基部分的新颖的噻唑烷酮-4-酮,并被评估为人类免疫缺陷病毒1型逆转录酶(HIV)的有效抑制剂。 -1 RT)。一种体外HIV-1 RT测定表明,该化合物4,5,6,8,12,13,14和17都示出高抑制逆转录酶(75.41,95.50,98.07,91.24,85.27,77.59,84.11&76.49的抑制百分比)的酶活性。此外,基于细胞的试验表明,化合物4,5,8&已确定12种分别是针对HIV-1 III B和HIV-1 ADA5菌株的最佳系列化合物(EC 50为0.09至0.8μg / ml和0.12至1.06μg / ml)。此外,还发现了具有抗HIV-1 III B和HIV-1 ADA5活性的化合物也具有抗主要分离株的活性(EC 50抗HIV-1 UG070的浓度范围为0.10至1.55μg/ ml,抗HIV-1